Active Ingredient: Immunoglobulins, normal human, IV
Immunomodulation in adults, and children and adolescents in Kawasaki disease (in conjunction with acetylsalicylic acid).
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 2 grams immunoglobulins, normal human, IV per kilogram of body weight, one dose.
2 g/kg should be administered as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.
Human normal immunoglobulin should be infused intravenously at an initial rate of 0.5 ml/kgBW/hr for 30 minutes. If well tolerated, the rate of administration may gradually be increased to a maximum of 6 ml/kgBW/hr.
Clinical data obtained from a limited number of patients also indicate that adult PID patients may tolerate an infusion rate of up to 8 ml/kg BW/hr.
Any infusion-related adverse events should be treated by lowering infusion rates or by stopping the infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
